Collectively, we propose that altered expression of Mad2-targeting miRNAs modulate SAC signaling, cellular senescence and microtubule drug response, and thereby contribute to the fates of individual cancer cells in the tumor tissue. The gene discussed is MAD2L1; the disease is neoplasm.